Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
The number of incident cases of AML in the Asia-Pacific countries under study will increase by 36%, from 10,500 to 14,200, in ten years. Of the countries considered in this analysis, the…
The number of incident cases of AML in the countries under study will increase by 33%, from 3,866 to 5,116, in ten years. Of the countries considered in this analysis, the incidence of AML is…
The number of incident cases of AML in the countries under study will increase by 38%, from 3,150 to 4,300, in ten years. Of the countries considered in this analysis, the incidence of AML is…
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
The number of incident cases of AML in the European countries under study will increase by 18%, from 5,876 to 6,932, in ten years. Of the countries considered in this analysis, the incidence of…
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country,…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of vitiligo for each country…
DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report the diagnosed prevalence of vitiligo for each country, as well as…
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…
MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted agents…